American Heart Journal
Volume 147, Issue 5 , Pages 924-930 , May 2004

Are hematinic deficiencies the cause of anemia in chronic heart failure?

  • Klaus K.A Witte, MRCP

      Affiliations

    • Division of Academic Cardiology, Castle Hill Hospital, Cottingham, United Kingdom
    • Corresponding Author InformationReprint requests: K Witte, MRCP, Academic Cardiology, Castle Hill Hospital, Castle Road, Cottingham, Hull HU16 5JQ UK.
    • ,
  • Ramesh Desilva, MRCP

      Affiliations

    • Division of Academic Cardiology, Castle Hill Hospital, Cottingham, United Kingdom
    • ,
  • Sudipta Chattopadhyay, MRCP

      Affiliations

    • Division of Academic Cardiology, Castle Hill Hospital, Cottingham, United Kingdom
    • ,
  • Justin Ghosh, MRCP

      Affiliations

    • Division of Academic Cardiology, Castle Hill Hospital, Cottingham, United Kingdom
    • ,
  • John G.F Cleland, MD

      Affiliations

    • Division of Academic Cardiology, Castle Hill Hospital, Cottingham, United Kingdom
    • ,
  • Andrew L Clark, MD

      Affiliations

    • Division of Academic Cardiology, Castle Hill Hospital, Cottingham, United Kingdom

Received 19 June 2003 ,Accepted 11 November 2003.

References 

  1. Horwich TB, Fonarow GC, Hamilton MA, et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780–1786
  2. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure (what is its frequency in the UK and its underlying causes?). Heart. 2002;87:377–378
  3. Silverberg DS, Wexler D, Blum M, et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–1744
  4. Maeda K, Tanaka Y, Tsukano ??, et al.  Multivariate analysis using a linear discriminant function for predicting the prognosis if congestice heart failure. Jpn Circ J. 1982;46:137–142
  5. Volpe M, Tritto C, Testa U, et al.  Blood levels of erythropoeitin in congestive heart failure and correlation with clinical, hemodynamic and hormonal profiles. Am J Cardiol. 1994;74:468–473
  6. Silverberg DS, Wexler D, Sheps D, et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron (a randomized controlled study). J Am Coll Cardiol. 2001;37:1775–1780
  7. Silverberg DS, Wexler D, Blum M, et al.  Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int. 2001;21(Suppl 3):S236–240
  8. Mancini DM, Katz SD, Lang CC, et al.  Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–299
  9. A study to assess the pharamcokinetics and pharmacodynamics of repeat-dose subcutaneous Darbopoetin Alfa in subjects with congestive heart failure and anaemia and a single dose in age- and sex-matched control subjects. Breda, The Netherlands: Amgen Development; 2001
  10. Macdougall IC, Tucker B, Thompson J, et al.  A randomised controlled study of iron supplementation in patients treated with erythropoetin. Kidney Int. 1996;50:1694–1699
  11. Schwengel RH, Gottlieb SS, Fisher ML. Protein-energy malnutrition in patients with ischemic and non-ischemic dilated cardiomyopathy. Am J Cardiol 1994;73:908–10
  12. King D, Smith ML, Chapman TJ, et al.  Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996;25:144–149
  13. Weil J, Colin JD, Langman M, et al.  Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J. 1995;310:827–830
  14. Silagy CA, McNeil JJ, Donnan GA, et al.  Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther. 1993;54:84–89
  15. Donnelly SM, Posen GA, Ali MA. Oral iron absorption in hemodialysis patients treated with erythropoetin. Clin Invest Med. 1991;14:271–276
  16. Griffing GT, Melby JC. Enalapril (MK–420) and the white cell count and hematocrit. Lancet. 1982;1:1361
  17. Fyhrquist F, Karppinen K, Honkannen T, et al.  High serum eryth-erythropoietin levels are normalised during treatment of congestive heart failure with enalapril. J Intern Med. 1989;226:257–260
  18. Kamper AL, Nielson OJ. Effect of enalapril on hemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest. 1990;50:611–618
  19. Hirakata H, Onayama K, Iseki K, et al.  Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol. 1984;4:355–360
  20. Yoshida A, Morozumi K, Suganuma T, et al.  Angiotensin- converting enzyme inhibitor and anemia in a patient undergoing hemodialysis. Nephron. 1991;59:334–335
  21. Hirakata H, Onayama K, Hori K, et al.  Participation of the renin–angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol. 1986;26:27–32
  22. Guyatt GH, Sullivan MJ, Thompson PJ, et al.  The 6-minute walk (a new measure of exercise capacity in patients with chronic heart failure). Can Med Assoc J. 1985;132:919–923
  23. Borg G. Subjective effort and physical activities. Scand J Rehab. 1978;6:108–113
  24. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting the anaerobic threshold by gas exchange. J Appl Physiol. 1986;60:2020–2027
  25. Schiller NB, Shah PM, Crawford M, et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–367
  26. Cleland JG, Tendera M, Adamus J, et al.  The PEP investigators   Perindopril for elderly people with chronic heart failure (the PEP-CHF study). Eur J Heart Fail. 1999;1:211–217
  27. McClellan WM, Flanders WD, Langston RD, et al.  Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals (a population-based study). J Am Soc Nephrol. 2002;13:1928–1936
  28. Androne AS, Katz SD, Lund L, et al.  Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107:226–229
  29. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes (insights from a cohort of 12,065 patients with new-onset heart failure). Circulation. 2003;107:223–225
  30. Witte KKA, Clark AL. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol. 2002;85(Suppl):23–31
  31. Conlon PJ, Albers F, Butterly D, et al.  ACE inhibitors do not affect erythropoietin efficacy in hemodialysis patients. Nephrol Dial Transplant. 1994;9:1358
  32. Cruz DN, Perazella MA, Abu-Alfa AK, et al.  Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients (any evidence of erythropoietin resistance?). Am J Kidney Dis. 1996;4:535–540
  33. Beckingham IJ, Woodrow G, Hinwood M, et al.  A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplant. 1995;10:2316–2320
  34. Nakao K, Shirakura T, Azuma M, et al.  Study of erythroid erythropoietic action of angiotensin II. Blood. 1967;29:754–760
  35. Gould AB, Goodman SA, DeWolf R, et al.  Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med. 1980;96:523–534
  36. Perazella M, McPhedran P, Kliger A, et al.  Enalapril treatment of posttransplant erythrocytosis (efficacy independent of circulating erythropoietin levels). J Kidney Dis. 1995;26:495–500
  37. Islam MS, Bourbigot B, Codet JP, et al.  Captopril induces correction of postrenal transplant erythremia. Transplant Int. 1990;3:222–225
  38. Rostaing L, Demur C, Huyn A, et al.  Erythrocytosis after renal transplant (study of erythroid progenitors and response to enalapril). Transplant Proc. 1994;26:280–281
  39. Beckingham IJ, Woodrow G, Hinwood M, et al.  A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplant. 1995;10:2316–2320

PII: S0002-8703(03)00795-6

doi: 10.1016/j.ahj.2003.11.007

American Heart Journal
Volume 147, Issue 5 , Pages 924-930 , May 2004

Article Tools

* Image Usage & Resolution